MS is the leading cause of non-traumatic disability in adults over the age of 50 and has become a focus of evolving research. In just the past two decades, a greater understanding of the pathogenesis of MS has led to a litany of new FDA approved therapies. In fact, there are now 18 DMTs representing nine therapeutic classes approved for use in the US with multiple late stage medications poised to join them. This curriculum is designed to help participants improve their MS management skills by distilling the most relevant and valuable information for their patients.

One out of six US adults suffer from migraines and yet, until recently, management has been reliant on treatments designed for other conditions that had some consequential success. Fortunately, this long-standing paradigm has not only ended but has accelerated in the opposite direction. The rapid acquisition of new therapies has created a near impossible amount of information to parse out efficiently. This curriculum is designed to help participants improve their migraine management skills by distilling what information is most relevant in the evolving world and what it means for patients. The activity features an in-depth interview with a renowned headache specialist, Dr Shivang Joshi, regarding the appropriate application of recent advances in headache medicine. Throughout the activity, Dr Joshi reviews his own management approaches for a variety of scenarios relevant to modern practice as well as those of the other experts involved in this project.